Published on in Vol 10, No 10 (2021): October
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/24969, first published
.
![Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study) Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)](https://asset.jmir.pub/assets/a760afe7699afa1e8d99efdc348bd0b6.png 480w,https://asset.jmir.pub/assets/a760afe7699afa1e8d99efdc348bd0b6.png 960w,https://asset.jmir.pub/assets/a760afe7699afa1e8d99efdc348bd0b6.png 1920w,https://asset.jmir.pub/assets/a760afe7699afa1e8d99efdc348bd0b6.png 2500w)
Journals
- Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A, Khalil M, Trinka E, Harrer A, Wipfler P, Moser T. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences 2023;24(4):4067 View
- Giovannoni G, Mathews J. Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review. Neurology and Therapy 2022;11(2):571 View
- Centonze D, Amato M, Brescia Morra V, Cocco E, De Stefano N, Gasperini C, Gallo P, Pozzilli C, Trojano M, Filippi M. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Therapeutic Advances in Neurological Disorders 2023;16 View
- Aran K, Gupta G, Singh S. Cryptotanshinone ameliorates cladribine-induced cognitive impairment in rats. Asian Pacific Journal of Tropical Biomedicine 2023;13(7):296 View